The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Molecular pathogenesis of malignant mesothelioma
Abstract
Malignant mesothelioma (MM) is an aggressive tumor arising primarily from the pleural or peritoneal cavities. It develops by asbestos exposure after a long latency, which is characterized by insidious growth and clinical presentation at an advanced stage of disease. MM is highly refractory to conventional therapies even with a combination of aggressive surgical intervention and multimodality strategies, with cure remaining elusive. Molecular genetic analysis has revealed several key genetic alterations, which are responsible for the development and progression of MM. The cyclin-dependent kinase inhibitor 2A/alternative reading frame (CDKN2A/ARF), neurofibromatosis type 2 (NF2) and BRCA1-associated protein-1 (BAP1) genes are the most frequently mutated tumor suppressor genes detected in MM cells; the alterations of the latter two are relatively characteristic of MM. Merlin, which is encoded by NF2, regulates multiple cell signaling cascades including the Hippo and mammalian target of rapamycin pathways, which regulate cell proliferation and growth. BAP1 is involved in histone modification and its inactivation induces the disturbance of global gene expression profiling. The discovery of a new familial cancer syndrome with germline mutation of BAP1 also indicates the importance of genetic factors in MM susceptibility. Meanwhile, although frequent expression and functional activations of oncogene products such as receptor tyrosine kinases are observed in MM cells, activating mutations of these genes are rare. With further comprehensive genome analyses, new genetic and epigenetic alterations in MM cells are expected to be revealed more precisely, and the new knowledge based on them will be applied for developing new diagnostic tools and new target therapies against MMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
The Hippo Signaling Pathway in Development and Cancer
Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.09.011 · Cited by 2,269
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
BAP1 loss defines a new class of renal cell carcinoma
Peña-Llopis, S., Vega-Rubín-de-Celis, S., Liao, A., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2323 · Cited by 959
Donaldson, K., Murphy, F. A., Duffin, R., & Poland, C. A. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-5 · Cited by 916
Advances in Malignant Mesothelioma
Robinson, B. W. S., & Lake, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050152 · Cited by 889
Germline mutations in BAP1 predispose to melanocytic tumors
Wiesner, T., Obenauf, A. C., Murali, R., Fried, I., Griewank, K. G., Ulz, P., Windpassinger, C., Wackernagel, W., Loy, S., Wolf, I., et al. (2011) · Nature Genetics · doi:10.1038/ng.910 · Cited by 725
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Nagai, H., Okazaki, Y., Chew, S. H., Misawa, N., Yamashita, Y., Akatsuka, S., Ishihara, T., Yamashita, K., Yoshikawa, Y., Yasui, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110013108 · Cited by 535
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Inhaled carbon nanotubes reach the subpleural tissue in mice
Ryman-Rasmussen, J. P., Cesta, M. F., Brody, A. R., Shipley-Phillips, J. K., Everitt, J. I., Tewksbury, E. W., Moss, O. R., Wong, B. A., Dodd, D. E., Andersen, M. E., et al. (2009) · Nature Nanotechnology · doi:10.1038/nnano.2009.305 · Cited by 463
Biochimica et biophysica acta. Protein structure and molecular enzymology
ScienceDirect (2002) · Cited by 395
Bianchi, A. B., Mitsunaga, S. I., Cheng, J. Q., Klein, W. M., Jhanwar, S. C., Seizinger, B., Kley, N., Klein-Szanto, A. J., & Testa, J. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.10854 · Cited by 360
Husain, A. N., Colby, T. V., Ordóñez, N. G., Krausz, T., Borczuk, A., Cagle, P. T., Chirieac, L. R., Churg, A., Galateau-Salle, F., Gibbs, A. R., et al. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.8.1317 · Cited by 332
Yang, H., Bocchetta, M., Kroczynska, B., Elmishad, A. G., Chen, Y., Liu, Z., Bubici, C., Mossman, B. T., Pass, H. I., Testa, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604008103 · Cited by 322
Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus
Li, W., You, L., Cooper, J., Schiavon, G., Pepe-Caprio, A., Zhou, L., Ishii, R., Giovannini, M., Hanemann, C. O., Long, S. B., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.029 · Cited by 321
James, M. F., Han, S., Polizzano, C., Plotkin, S. R., Manning, B. D., Stemmer-Rachamimov, A. O., Gusella, J. F., & Ramesh, V. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01581-08 · Cited by 306
Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer
(1995) · Lung Cancer · doi:10.1016/0169-5002(95)90162-0 · Cited by 296
Yang, H., Rivera, Z., Jube, S., Nasu, M., Bertino, P., Goparaju, C., Franzoso, G., Lotze, M. T., Krausz, T., Pass, H. I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006542107 · Cited by 281
Mizuno, T., Murakami, H., Fujii, M., Ishiguro, F., Tanaka, I., Kondo, Y., Akatsuka, S., Toyokuni, S., Yokoi, K., Osada, H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.5 · Cited by 279
Self-citationLATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma
Murakami, H., Mizuno, T., Taniguchi, T., Fujii, M., Ishiguro, F., Fukui, T., Akatsuka, S., Horio, Y., Hida, T., Kondo, Y., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2164 · Cited by 263
Self-citationGuled, M., Lahti, L., Lindholm, P. M., Salmenkivi, K., Bagwan, I., Nicholson, A. G., & Knuutila, S. (2009) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20669 · Cited by 259
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
Carbone, M., Emri, S., Dogan, A. U., Steele, I., Tuncer, M., Pass, H. I., & Baris, Y. I. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2068 · Cited by 253
TGF-β Synergizes with Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth
Fujii, M., Toyoda, T., Nakanishi, H., Yatabe, Y., Sato, A., Matsudaira, Y., Ito, H., Murakami, H., Kondo, Y., Kondo, E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111653 · Cited by 224
Self-citationDiagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
Chiosea, S., Krasinskas, A., Cagle, P. T., Mitchell, K. A., Zander, D. S., & Dacic, S. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.45 · Cited by 207
López-Lago, M. A., Okada, T., Murillo, M. M., Socci, N., & Giancotti, F. G. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01578-08 · Cited by 184
Heintz, N. H., Janssen-Heininger, Y. M. W., & Mossman, B. T. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0206tr · Cited by 182
Nagoya Journal of Medical Science
(1964) · JAMA · doi:10.1001/jama.1964.03060370134082 · Cited by 181
Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
Yoshikawa, Y., Sato, A., Tsujimura, T., Emi, M., Morinaga, T., Fukuoka, K., Yamada, S., Murakami, A., Kondo, N., Matsumoto, S., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02223.x · Cited by 179
MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications
Busacca, S., Germano, S., De Cecco, L., Rinaldi, M., Comoglio, F., Favero, F., Murer, B., Mutti, L., Pierotti, M., & Gaudino, G. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0060oc · Cited by 167
Christensen, B. C., Houseman, E. A., Godleski, J. J., Marsit, C. J., Longacker, J. L., Roelofs, C. R., Karagas, M. R., Wrensch, M., Yeh, R.-F., Nelson, H. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2586 · Cited by 164
Functional inactivation of NF2/merlin in human mesothelioma
Thurneysen, C., Opitz, I., Kurtz, S., Weder, W., Stahel, R. A., & Felley‐Bosco, E. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.08.014 · Cited by 162
Transcriptome sequencing of malignant pleural mesothelioma tumors
Sugarbaker, D. J., Richards, W. G., Gordon, G. J., Dong, L., De Rienzo, A., Maulik, G., Glickman, J. N., Chirieac, L. R., Hartman, M.-L., Taillon, B. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712399105 · Cited by 155
A Mouse Model Recapitulating Molecular Features of Human Mesothelioma
Altomare, D. A., Vaslet, C. A., Skele, K. L., Rienzo, A. D., Devarajan, K., Jhanwar, S. C., McClatchey, A. I., Kane, A. B., & Testa, J. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2312 · Cited by 154
hsa-miR-29c* Is Linked to the Prognosis of Malignant Pleural Mesothelioma
Pass, H. I., Goparaju, C. M. V., Ivanov, S. V., Donington, J. S., Carbone, M., Hoshen, M., Cohen, D., Chajut, A., Rosenwald, S., Dan, H., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3993 · Cited by 152
An Emerging Model for BAP1’s Role in Regulating Cell Cycle Progression
Eletr, Z. M., & Wilkinson, K. D. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9184-6 · Cited by 150
Barbone, D., Yang, T., Morgan, J. R., Gaudino, G., & Broaddus, V. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709698200 · Cited by 149
A Conditional Mouse Model for Malignant Mesothelioma
Jongsma, J., van Montfort, E. H. N., Vooijs, M., Zevenhoven, J., Krimpenfort, P., van der Valk, M., van de Vijver, M. J., & Berns, A. J. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.030 · Cited by 138
Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma
Ivanov, S. V., Goparaju, C. M. V., Lopez, P., Zavadil, J., Toren-Haritan, G., Rosenwald, S., Hoshen, M., Chajut, A., Cohen, D., & Pass, H. I. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100354 · Cited by 129
Epigenetic Profiles Distinguish Malignant Pleural Mesothelioma from Lung Adenocarcinoma
Gotô, Y., Shinjo, K., Kondo, Y., Shen, L., Toyota, M., Suzuki, H., Gao, W., An, B., Fujii, M., Murakami, H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1595 · Cited by 128
Self-citationWu, D., Hiroshima, K., Matsumoto, S., Nabeshima, K., Yusa, T., Ozaki, D., Fujino, M., Yamakawa, H., Nakatani, Y., Tada, Y., et al. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpt94jvwihbkrd · Cited by 119
Dubey, S., Janne, P. A., Krug, L. M., Pang, H., Wang, X., Heinze, R., Watt, C., Crawford, J., Kratzke, R. A., Vokes, E. E., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ec18db · Cited by 116
Liu, W., Ernst, J. D., & Broaddus, V. C. (2000) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.23.3.4094 · Cited by 113
Yokoyama, T., Osada, H., Murakami, H., Tatematsu, Y., Taniguchi, T., Kondo, Y., Yatabe, Y., Hasegawa, Y., Shimokata, K., Horio, Y., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn200 · Cited by 110
Self-citationCytogenetic and molecular genetic changes in malignant mesothelioma
Musti, M., Kettunen, E., Dragonieri, S., Lindholm, P., Cavone, D., Serio, G., & Knuutila, S. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.04.011 · Cited by 108
Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Kemp, C. D., Rao, M., Xi, S., Inchauste, S. M., Mani, H., Fetsch, P. A., Filie, A. C., Zhang, M. F., Hong, J. A., Walker, R. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0962 · Cited by 108
Molecular Changes in Mesothelioma With an Impact on Prognosis and Treatment
Jean, D., Daubriac, J., Pimpec‐Barthes, F. L., Galateau-Sallé, F., & Jaurand, M. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0215-ra · Cited by 104
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
Garland, L. L., Chansky, K., Wozniak, A. J., Tsao, A. S., Gadgeel, S. M., Verschraegen, C. F., DaSilva, M. A., Redman, M. W., & Gandara, D. R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318229586e · Cited by 97
Cheng, J. Q., Lee, W.-C., Klein, M. A., Cheng, G. Z., Jhanwar, S. C., & Testa, J. R. (1999) · Genes Chromosomes and Cancer · Cited by 96
Fischer, J. R., Ohnmacht, U., Rieger, N., Žemaitis, M., Stoffregen, C., Kostrzewa, M., Buchholz, E., Manegold, C., & Lahm, H. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.06.017 · Cited by 93
Malignant pleural mesothelioma
Pass, H. I., Vogelzang, N. J., Hahn, S. M., & Carbone, M. (2004) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2004.04.001 · Cited by 79
Røe, O. D., Anderssen, E., Sandeck, H., Christensen, T., Larsson, E., & Lundgren, S. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.03.016 · Cited by 78
Altomare, D. A., Menges, C. W., Pei, J., Zhang, L., Skele, K. L., Carbone, M., Kane, A. B., & Testa, J. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808816106 · Cited by 76
Brevet, M., Shimizu, S., Bott, M. J., Shukla, N. N., Zhou, Q., Olshen, A. B., Rusch, V. W., & Ladanyi, M. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318215a07d · Cited by 75
Onofre, F. B. D. M., Onofre, A. S. C., Pomjanski, N., Buckstegge, B., Grote, H. J., & Böcking, A. (2008) · Cancer · doi:10.1002/cncr.23413 · Cited by 75
Laurie, S. A., Gupta, A. K., Chu, Q. S.-C., Lee, C. W., Morzycki, W., Feld, R. D., Foo, A. H., Seely, J. M., Goffin, J. R., Laberge, F., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182333df5 · Cited by 70
Altomare, D. A., Menges, C. W., Xu, J., Pei, J., Zhang, L., Tadevosyan, A., Neumann-Domer, E., Liu, Z., Carbone, M., Chudoba, I., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018828 · Cited by 65
Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma
Hu, Q., Akatsuka, S., Yamashita, Y., Ohara, H., Nagai, H., Okazaki, Y., Takahashi, T., & Toyokuni, S. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2009.140 · Cited by 62
Matsumoto, S., Nabeshima, K., Kamei, T., Hiroshima, K., Kawahara, K., Sakae, H. A. T. A., Marukawa, K., Matsuno, Y., Taguchi, K., & Tsujimura, T. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21269 · Cited by 62
Lončarević, I., Roitzheim, B., Ritterbach, J., Viehmann, S. F., Borkhardt, A., Lampert, F. H., & Harbott, J. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199903)24:3<238::aid-gcc9>3.3.co;2-d · Cited by 61
Menges, C. W., Chen, Y., Mossman, B. T., Chernoff, J., Yeung, A. T., & Testa, J. R. (2010) · Genes & Cancer · doi:10.1177/1947601910375273 · Cited by 57
Campbell, N. P., Kunnavakkam, R., Leighl, N. B., Vincent, M. D., Gandara, D. R., Koczywas, M., Gitlitz, B. J., Agamah, E. S., Thomas, S. P., Stadler, W. M., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.06.011 · Cited by 55
Varghese, S., Chen, Z., Bartlett, D. L., Pingpank, J. F., Libutti, S. K., Steinberg, S. M., Wunderlich, J. R., & Alexander, H. R. (2010) · Cancer · doi:10.1002/cncr.25555 · Cited by 53
Christensen, B. C., Houseman, E. A., Poage, G. M., Godleski, J. J., Bueno, R., Sugarbaker, D. J., Wiencke, J. K., Nelson, H. H., Marsit, C. J., & Kelsey, K. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0190 · Cited by 53
Review on clinical trials of targeted treatments in malignant mesothelioma
Jakobsen, J. N., & Sørensen, J. B. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1655-3 · Cited by 48
Merlin: The wizard requires protein stability to function as a tumor suppressor
Morrow, K. A., & Shevde, L. A. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.005 · Cited by 43
Takeda, M., Kasai, T., Enomoto, Y., Takano, M., Morita, K., Kadota, E., Iizuka, N., Maruyama, H., & Nonomura, A. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200208 · Cited by 42
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma
Hartman, M.-L., Esposito, J. M., Yeap, B. Y., & Sugarbaker, D. J. (2009) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2009.06.027 · Cited by 29
Factors that Impact Susceptibility to Fiber-Induced Health Effects
Below, J. E., Cox, N. J., Fukagawa, N. K., Hirvonen, A., & Testa, J. R. (2011) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2011.556052 · Cited by 25
DNA repair systems in malignant mesothelioma
Toumpanakis, D., & Theocharis, S. E. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.021 · Cited by 24
(1995) · PubMed
(2009) · doi:10.18999/nagjms.71.1-2.1
(2003) · PubMed
Cited by
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0804 · Cited by 618
Self-citationNovel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Bibby, A. C., Tsim, S., Kanellakis, N., Ball, H., Talbot, D. C., Blyth, K. G., Maskell, N. A., & Psallidas, I. (2016) · European Respiratory Review · doi:10.1183/16000617.0063-2016 · Cited by 316
The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases
Sayan, M., & Mossman, B. T. (2015) · Particle and Fibre Toxicology · doi:10.1186/s12989-016-0162-4 · Cited by 296
Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215
Metadata
- Authors
- Sekido, Y.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-05-14
- Volume
- 34
- Issue
- 7
- Pages
- 1413-1419
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2161488572
- Cited by
- 279
- References
- 76
- FWCI
- 17.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.